Pembrolizumab - Biologic Drug Details

Summary for pembrolizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for pembrolizumab

Recent Clinical Trials for pembrolizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Exelixis	PHASE2
Lepu Medical Technology (Beijing) Co., Ltd.	PHASE2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	PHASE2

See all pembrolizumab clinical trials

Pharmacology for pembrolizumab

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pembrolizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pembrolizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2038-09-27	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-11-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2041-09-02	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2041-06-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for pembrolizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2036-06-24	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-02-04	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-08-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-06-16	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-07-25	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-03-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2036-12-21	Patent claims search

International Patents for pembrolizumab

Country	Patent Number	Estimated Expiration
Japan	2015504666
European Patent Office	2170959
Russian Federation	2013148537
Spain	2749620
Singapore	10201914022Q
Japan	5191537
South Korea	20140026434

Supplementary Protection Certificates for pembrolizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1591078-9	Sweden		PRODUCT NAME: PEMBROLIZUMAB; FIRST MARKETING AUTHORIZATION NUMBER: EU/1/15/1024, 2015-07-21
SPC/GB15/084	United Kingdom		PRODUCT NAME: PEMBROLIZUMAB; REGISTERED: UK EU/1/15/1024 (NI) 20150721
C02170959/01	Switzerland		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65440 10.09.2015
PA2016001	Lithuania		PRODUCT NAME: PEMBROLIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1024/001 20150717
1690001-1	Sweden		PRODUCT NAME: PEMBROLIZUMAB; REG. NO/DATE: EU/1/15/1024 20150721
1590078-0	Sweden		PRODUCT NAME: PEMBROLIZUMAB; REG. NO/DATE: EU/1/15/1024 20150721
C01537878/02	Switzerland		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65440 10.09.2015

Market Dynamics and Financial Trajectory of Pembrolizumab

Last updated: March 2, 2026

How does the market for pembrolizumab evolve across oncology indications?

Pembrolizumab, marketed as Keytruda by Merck & Co., has become a leading immune checkpoint inhibitor. Its market presence covers multiple cancer types, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, Hodgkin lymphoma, bladder cancer, and others.

Since FDA approval in 2014 for melanoma, pembrolizumab's indications expanded rapidly, driven by clinical trial successes that demonstrated improved survival.

Market penetration is highest in NSCLC, with specific approvals for both first-line and subsequent therapy. Approval trajectories for other indications follow, including gastric, cervical, and colorectal cancers.

Growth factors include:

• Broadening second-line and combination therapy approvals.
• Expanding into earlier-stage diseases.
• Growing global treatment adoption, particularly across high-income markets.

What are the revenue and sales trends for pembrolizumab?

Merck reports Keytruda revenues; globally, Keytruda generated approximated USD 13.2 billion in sales for full-year 2022. Sales grew at a compound annual growth rate (CAGR) of 27% over the prior five years.

Quarterly sales exhibit consistent growth, with the US accounting for about 70% of revenue. China and other regions collectively constitute roughly 20-25%. International sales demonstrate rapid growth, especially after regulatory approvals in China beginning in 2018.

For context:	Year	Global Sales (USD billion)	Year-over-Year Growth
2018	6.3	60%
2019	8.0	27%
2020	10.4	30%
2021	12.4	19%
2022	13.2	6.5%

These figures include sales from both monotherapy and combination regimens.

What are the competitive and regulatory factors impacting sales?

Pembrolizumab faces competition from other PD-1/PD-L1 inhibitors, notably nivolumab (Opdivo), durvalumab (Imfinzi), and atezolizumab (Tecentriq). Nivolumab's market share remains significant, especially in NSCLC and melanoma.

Increased competition from biosimilars is unlikely within the next five years due to patent protections. Merck holds key patents expiring between 2028 and 2034, with some litigation ongoing.

Regulatory approvals expand the market:

• Recently approved in combination with chemotherapy for gastric and gastroesophageal junction cancers.
• Approvals extend into adjuvant and neoadjuvant settings.
• Biosimilar entry remains unlikely before 2030, maintaining monopolistic revenue streams.

How do pipeline developments affect future financial forecasts?

Merck's pipeline includes more than ten clinical programs involving pembrolizumab:

• New indications: triple-negative breast cancer, non-muscle-invasive bladder cancer, and solid tumors.
• Novel combinations: with targeted therapies and other immunotherapies.
• Adjuvant and neoadjuvant trials expanding treatment lines.

Successful trial results could prolong revenue growth into the next decade. Failures or delays could impact projections, making pipeline monitoring crucial.

Projected revenue contributions:	Year	Additional Revenue (USD billion)	Notes
2024	+1.2	Pending approval for additional indications
2025	+2.0	Launch of new combination regimens
2026	+2.5	Expanded approvals in early-stage settings

What are the pricing and reimbursement trends?

Pricing varies globally:

• U.S.: Average wholesale price (AWP) exceeds USD 150,000 per year for monotherapy.
• China: Price reductions following regulatory negotiations, with national price caps around USD 60,000 annually.
• Europe: Prices average USD 125,000 annually, but vary by country.

Reimbursement coverage is extensive in high-income regions, supported by health technology assessments (HTAs). Cost-effectiveness is debated; however, the drug’s survival benefits sustain reimbursement.

Key Challenges and Opportunities

Challenges:

• Intense competition with nivolumab, especially in overlapping indications.
• Possibility of market saturation in mature indications.
• Cost pressure from payers limiting price increases.
• Regulatory and IP risks influencing revenue timelines.

Opportunities:

• Broader approval in earlier disease stages.
• New combinations with targeted therapies for synergistic effects.
• Expanding into markets with lower per capita healthcare spend through partnerships or price adjustments.

---

Key Takeaways

• Pembrolizumab's global sales reached USD 13.2 billion in 2022, with sustained growth driven by multiple indications.
• The drug faces stiff competition from nivolumab, but patent protections delay biosimilar entry until after 2028.
• Pipeline advances and new approvals support revenue growth through 2025-2026.
• Pricing strategies vary globally, impacting overall revenue and market penetration.
• Future growth hinges on pipeline success, competitive dynamics, and regulatory environments.

---

FAQs

1. When does Merck expect to see peak sales for pembrolizumab?
Peak sales are projected between 2024 and 2026, contingent on pipeline approvals and market expansion.

2. How vulnerable is pembrolizumab to biosimilar competition?
Patents provide protection until approximately 2028-2034, delaying biosimilar entry.

3. Which markets are most critical for future growth?
The U.S., China, and Europe remain dominant. Expanding into Asia-Pacific and Latin America presents growth potential.

4. What are key regulatory hurdles for new indications?
Complete phase III trial data demonstrating survival benefits and manageable safety profiles are required, with approval timelines varying by region.

5. How do pricing pressures affect Merck’s revenue targets?
Pricing reductions in some markets and payer cost controls limit revenue growth, necessitating innovation and pipeline diversification.

---

References

1. Merck & Co. (2023). Annual Report 2022.
2. IQVIA. (2022). Global Oncology Trends.
3. FDA. (2022). Approval history for pembrolizumab.
4. European Medicines Agency. (2022). Summary of product characteristics for Keytruda.
5. Frost & Sullivan. (2022). Oncology immunotherapy market outlook.